Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation SAN DIEGO, Feb. 28, 2020 /PRNewswire/ — HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, has presented the results of a Phase I study of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF). […]